A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

According to the Washington Post, 13 states currently cover the drugs for Medicaid patients, while Medicare prohibits ...

Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock gain as Trump administration to trial Medicare, Medicaid coverage for ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

The Trump administration outlines a plan to cover weight-loss drugs under Medicare and Medicaid, allowing certain state ...

The Trump administration is planning an experiment to cover weight-loss drugs under Medicare and Medicaid, the Washington ...

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...

The Trump administration is considering a proposal to allow Medicare and Medicaid to cover expensive weight-loss drugs. GLP-1 ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.